Product Description
ABBV-176 is an antibody-drug conjugate composed of the humanized antibody h16f (PR-1594804) conjugated to a highly potent, cytotoxic cross-linking pyrrolobenzodiazepine dimer (PBD; SGD-1882) targeting the prolactin receptor (PRLR), which is overexpressed in several solid tumor types. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/32524319/)
Mechanisms of Action: Prolactin Receptor Modulator
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Renal Cell Carcinoma|Adrenocortical Carcinoma|Hepatocellular Carcinoma|Breast Cancer|Colorectal Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03145909 |
PRLR | P1 |
Terminated |
Colorectal Cancer|Renal Cell Carcinoma|Hepatocellular Carcinoma|Breast Cancer|Adrenocortical Carcinoma |
2018-11-27 |
47% |
2019-03-21 |